Cover - USD ($) $ / shares in Units, $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Jun. 30, 2025 |
Mar. 31, 2025 |
|
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | bioAffinity Technologies, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025 (the “Original Filing”).This Amendment is being filed for the sole purpose of including the information required by Part III of the Annual Report on Form 10-K that was intended to be incorporated by reference to the Company’s definitive proxy statement relating to the 2025 annual meeting of stockholders because such proxy statement will not be filed with the Securities and Exchange Commission within 120 days after the end of the Company’s fiscal year ended December 31, 2024. As required by the SEC, this Amendment includes new certifications pursuant to Sections 302 of the Sarbanes-Oxley Act of 2002, filed as Exhibits 31.3, 31.4, hereto. Because no financial statements are contained within this Amendment, we are not filing currently dated certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This Amendment has not been updated or amended to give effect to any subsequent events beyond those that existed as of the original filing date and should thus be read in conjunction with the Original Filing and any of the Company’s other filings with the SEC subsequent to the Original Filing, together with any amendments to those filings. Other than the filing of the information identified above, this amendment does not modify or update the disclosure in the Original Filing in any way. Unless otherwise specified or the context otherwise requires, when used in this Amendment, the terms “we,” “our,” “us,” “bioAffinity,” or the “Company” refer to bioAffinity Technologies, Inc. and its subsidiaries. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2024 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-41463 | ||
| Entity Registrant Name | bioAffinity Technologies, Inc. | ||
| Entity Central Index Key | 0001712762 | ||
| Entity Tax Identification Number | 46-5211056 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 3300 Nacogdoches Road | ||
| Entity Address, Address Line Two | Suite 216 | ||
| Entity Address, City or Town | San Antonio | ||
| Entity Address, State or Province | TX | ||
| Entity Address, Postal Zip Code | 78217 | ||
| City Area Code | (210) | ||
| Local Phone Number | 698-5334 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Elected Not To Use the Extended Transition Period | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 22.6 | ||
| Entity Common Stock, Shares Outstanding | 18,255,824 | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Listing, Par Value Per Share | $ 0.007 | ||
| Common stock, par value $0.007 per share | |||
| Title of 12(b) Security | Common stock, par value $0.007 per share | ||
| Trading Symbol | BIAF | ||
| Security Exchange Name | NASDAQ | ||
| Tradeable Warrants to purchase Common Stock | |||
| Title of 12(b) Security | Tradeable Warrants to purchase Common Stock | ||
| Trading Symbol | BIAFW | ||
| Security Exchange Name | NASDAQ |